Hyderabad, Feb 8 : Granules India Limited, a vertically integrated pharmaceutical company, Today reported a 31 percent rise in its consolidated net profit at Rs 147 crore for the third quarter ended December in the current fiscal 2022-23. The profit after tax during the same quarter in the last fiscal was Rs 101 crore, Hyderabad-based pharmaceutical company said in a release here. The company’s Revenues increased by 18 per cent to Rs 997 crore during the quarter against Rs 845 crore in the corresponding period in the previous year. Revenue from Europe increased to 24.5 per cent when compared to 18.6 per cent Year-on-Year on account of increase in selling prices for Paracetamol tablet, the release said. There is increase in Paracetamol tablets across all the segments by INR 108 crore and increase in other molecules by INR 56 crore in view of steady market capture by newly launched molecules. During the quarter, the pharma company filed two ANDA, two Canadian Dossiers, one US DMF, one CEP and received three ANDA approvals. The Board of Directors has declared its third interim dividend of 25 paise per equity share of INR 1 each. Commenting on the results, Granules India Chairman and Managing Director Dr Krishna Prasad Chigurupati, said, we are slowly getting back to the normal as is evident from the revenue growth which came in despite the continuing disruptions and challenging environment such as raw material price increase, unstable supply from China and PAP supply constraints. We expect the situation to improve in coming quarters and remain focused on execution and agile to the market opportunities, he added. (UNI)